Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04525209
Recruitment Status : Not yet recruiting
First Posted : August 25, 2020
Last Update Posted : August 25, 2020
Sponsor:
Information provided by (Responsible Party):
HAOCHEN, Ruijin Hospital

Brief Summary:
A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.

Condition or disease Intervention/treatment
Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics Other: No intervention

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Intervention Details:
  • Other: No intervention
    No intervention


Primary Outcome Measures :
  1. Integrative Proteomic Characterization of PDAC [ Time Frame: Two yeaers ]
    The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC


Biospecimen Retention:   Samples With DNA
PDAC tumor and Non-tumor DNA, RNA, protein


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Chinese PDAC patients
Criteria

Inclusion Criteria:

  1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology;
  2. The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;

Exclusion Criteria:

  1. The inclusion criteria of the above groups were not met;
  2. There are few tissue specimens, only enough for clinical diagnosis;
  3. Patients are unwilling to conduct follow-up study;
  4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04525209


Contacts
Layout table for location contacts
Contact: Hao Chen, MD 13003135899 haochendr@126.com
Contact: Lingxi Jiang, Ph.D 13818826142 jlx12120@rjh.com.cn

Locations
Layout table for location information
China, Shanghai
RUIJIN Hospital
Shanghai, Shanghai, China, 200025
Contact: Jian Li, Ph.D         
Sponsors and Collaborators
Ruijin Hospital
Investigators
Layout table for investigator information
Principal Investigator: Hao Chen, MD Ruijin Hospital
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: HAOCHEN, Chen Hao, Ruijin Hospital
ClinicalTrials.gov Identifier: NCT04525209    
Other Study ID Numbers: 2020-08-20
First Posted: August 25, 2020    Key Record Dates
Last Update Posted: August 25, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms